Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

Subsidie
€ 2.966.695
2024

Projectdetails

THE CHALLENGE

Immunotherapy has revolutionized cancer treatment, but most patients do not respond due to immune evasion mechanisms, including heterogeneity and lack of tumor antigen presentation. Moreover, these therapies have met limited success in the treatment of solid tumors and are frequently associated with severe adverse effects.

RADICAL VISION

The radical vision of the RESYNC consortium is to revolutionize cancer immunotherapy through small-molecule (SM)-based reprogramming of cancer cells into immunogenic (neo)antigen-presenting dendritic cells type 1 (cDC1) to elicit a personalized anti-tumor immunity.

Cell reprogramming will be coupled with nanoparticle formulations enabling safe, low-cost, and efficient systemic targeting of disseminated tumors. The proposed platform will enable breakthrough innovations in the cellular reprogramming-based therapeutics space and have a broad and disruptive effect on the immune-oncology therapeutics scientific field and market.

With a complementary consortium, we expect to achieve proof-of-concept for chemical cDC1 reprogramming by the end of the project (2026).

IMPACT

This approach will for the first time harness the full potential of cellular reprogramming to induce immunity against tumor antigens with the tractability of systemic delivery of cDC1-inducing SMs.

This project will result in next-generation platforms for in vivo reprogramming and cell-targeted delivery of SMs with:

  • High cell specificity
  • Low price
  • Improved safety

SM-mediated antigen presentation will be combined with immune checkpoint blockade, enabling immunotherapy in all patients. Ultimately, this project will set the stage for a new era of personalized, off-the-shelf cancer immunotherapies.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.966.695
Totale projectbegroting€ 2.966.695

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2026
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • LUNDS UNIVERSITETpenvoerder
  • ASGARD THERAPEUTICS AB
  • POLITECNICO DI TORINO
  • UNIVERSITATEA BABES BOLYAI
  • USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.
  • KAROLINSKA INSTITUTET

Land(en)

SwedenItalyRomaniaCzechia

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy

The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.

€ 2.982.792
EIC Pathfinder

"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"

The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.

€ 2.996.550
EIC Pathfinder

Smart Electronic Olfaction for Body Odor Diagnostics

SMELLODI aims to digitize and synthesize olfactory information for remote disease diagnostics and assist individuals with olfactory disorders using advanced sensor technology and machine learning.

€ 3.263.781
EIC Pathfinder

Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.

The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.

€ 2.744.300

Vergelijkbare projecten uit andere regelingen

ERC STG

Polyclonal anti-tumor immunity by engineered human T cells

This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.

€ 1.812.500
ERC COG

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.

€ 1.993.875
ERC ADG

Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies

The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.

€ 2.500.000
ERC POC

Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy

ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.

€ 150.000